1
|
Gaudreault J, Schmidt A, Altevogt P, Spohn G. Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy268.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Yu Y, Gool E, Berckmans RJ, Coumans FAW, Barendrecht AD, Maas C, van der Wel NN, Altevogt P, Sturk A, Nieuwland R. Extracellular vesicles from human saliva promote hemostasis by delivering coagulant tissue factor to activated platelets. J Thromb Haemost 2018; 16:1153-1163. [PMID: 29658195 DOI: 10.1111/jth.14023] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Indexed: 02/06/2023]
Abstract
Essentials Human salivary extracellular vesicles (EVs) expose coagulant tissue factor (TF). Salivary EVs expose CD24, a ligand of P-selectin. CD24 and coagulant TF co-localize on salivary EVs. TF+ /CD24+ salivary EVs bind to activated platelets and trigger coagulation. SUMMARY Background Extracellular vesicles (EVs) from human saliva expose coagulant tissue factor (TF). Whether such TF-exposing EVs contribute to hemostasis, however, is unknown. Recently, in a mice model, tumor cell-derived EVs were shown to deliver coagulant TF to activated platelets at a site of vascular injury via interaction between P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin. Objectives We hypothesized that salivary EVs may deliver coagulant TF to activated platelets via interaction with P-selectin. Methods We investigated the presence of two ligands of P-selectin on salivary EVs, PSGL-1 and CD24. Results Salivary EVs expose CD24 but PSGL-1 was not detected. Immune depletion of CD24-exposing EVs completely abolished the TF-dependent coagulant activity of cell-free saliva, showing that coagulant TF and CD24 co-localize on salivary EVs. In a whole blood perfusion model, salivary EVs accumulated at the surface of activated platelets and promoted fibrin generation, which was abolished by an inhibitory antibody against human CD24. Conclusions A subset of EVs in human saliva expose coagulant TF and CD24, a ligand of P-selectin, suggesting that such EVs may facilitate hemostasis at a site of skin injury where the wound is licked in a reflex action.
Collapse
Affiliation(s)
- Y Yu
- Laboratory of Experimental Clinical Chemistry, Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, the Netherlands
- Vesicle Observation Centre, AMC, Amsterdam, the Netherlands
| | - E Gool
- Laboratory of Experimental Clinical Chemistry, Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, the Netherlands
- Vesicle Observation Centre, AMC, Amsterdam, the Netherlands
- Department of Biomedical Engineering and Physics, AMC, Amsterdam, the Netherlands
| | - R J Berckmans
- Laboratory of Experimental Clinical Chemistry, Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, the Netherlands
- Vesicle Observation Centre, AMC, Amsterdam, the Netherlands
| | - F A W Coumans
- Vesicle Observation Centre, AMC, Amsterdam, the Netherlands
- Department of Biomedical Engineering and Physics, AMC, Amsterdam, the Netherlands
| | - A D Barendrecht
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - C Maas
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - N N van der Wel
- Department of Medical Biology, Electron Microscopy Centre Amsterdam, AMC, Amsterdam, the Netherlands
| | - P Altevogt
- Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany
- Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany
| | - A Sturk
- Laboratory of Experimental Clinical Chemistry, Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, the Netherlands
- Vesicle Observation Centre, AMC, Amsterdam, the Netherlands
| | - R Nieuwland
- Laboratory of Experimental Clinical Chemistry, Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, the Netherlands
- Vesicle Observation Centre, AMC, Amsterdam, the Netherlands
| |
Collapse
|
3
|
Ratz L, Laible M, Altevogt P, Klauck S, Sültmann H. Overexpression of TMPRSS2:ERG variants activates TGF-β signaling and promotes invasion of prostate cancer cells. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61037-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Notaro S, Fiegl H, Reimer D, Duggan-Peer M, Wiedemair A, Rössler J, Altevogt P, Zeimet AG, Marth C. Evaluierung der L1CAM-Expression beim Endometriumkarzinom mittels quantitativer Real-time PCR. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
5
|
Wirtz RM, Aigner J, Marme F, Eidt S, Altevogt P, Sinn P, Schneeweiss A. Abstract P1-08-07: High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Immune cell infiltrates have been shown to play a prominent role with regard to prognosis of node negative breast cancer (Schmidt et al 2008). Moreover, it has been shown that B-cells and T-Cells are of particular importance for the response to chemotherapy (Schmidt et al. 2012). However, the role of macrophages remains unclear. It has been assumed, that tumor-associated macrophages play a role in promoting tumorigenesis. Still their role with regard to therapy prediction is unknown. Here we tested wether the infiltration of macrophages is associated with the response to neoadjuvant chemotherapy.
Materials and Methods
Pretreatment core cut biopsies from n = 100 patients with PBC treated within a randomized phase II trial (1) of anthracyline/taxane based NAC were examined. RNA from formalin-fixed, paraffin embedded (FFPE) routine biopsies were extracted using a bead-based extraction method (STRATIFYER XTRAKT kits). CD68 and ESR1, PGR, HER2, Ki67 as well as CALM2 as a house keeping gene were measured via a multiplex quantitative RT-PCR (RT-qPCR). Correlation analyses and partitioning tests were performed using the SAS JMP® 9.0.0 software.
Results
CD68 mRNA exhibited a normal data distribution (Median expression 40-DCT 34,66) in the core needle biopsies of advanced breast tumors. CD68 mRNA correlated strongly with Ki67 mRNA levels (Spearman r = 0,46; p<0,001), whereas there is virtually no correlation with other classical biomarkers such as ESR1, PGR and HER2. Partitioning analysis revealed that CD68 mRNA levels are superior to the previously and prospectively validated response markers ESR1 mRNA and HER2 mRNA. When using the median mRNA expression as an objective cut-off measurement no tumor having low CD68 mRNA expression did respond to chemotherapy, while 22% of the CD68 positive tumors responded by pathological complete response (ypT0ypN0). Based on molecular subtyping into Luminal, HER2 positive and Triple-Negative with predefined Cut-Off values for ESR1mRNA and HER2 mRNA levels, high CD68 were particularly informative within luminal tumors (22% pCR versus 0% pCR rate) and Triple negative tumors (38% pCR versus 0% pCR rate).
Conclusion
The presence of macrophages indicates tumors being sensitive to chemotherapy beyond the prospectively validated ESR1 and HER2 mRNA determinations (2), both in luminal and triple negative tumors. The mRNA expression levels of CD68 provide additional information beyond conventional subtyping and might therefore be useful for early assessment of non-response to chemotherapy und subsequent treatment planning.
1) Schneeweiss et al, Ann Oncol 2011
2) Denkert et al, Ann Oncol 2013.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-07.
Collapse
Affiliation(s)
- RM Wirtz
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - J Aigner
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - F Marme
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - S Eidt
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - P Altevogt
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - P Sinn
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - A Schneeweiss
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
6
|
Salnikov AV, Bretz NP, Perne C, Hazin J, Keller S, Fogel M, Herr I, Schlange T, Moldenhauer G, Altevogt P. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer 2013; 108:1449-59. [PMID: 23511563 PMCID: PMC3629417 DOI: 10.1038/bjc.2013.102] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background: The targeting of cancer stem cells by monoclonal antibodies offers new options for therapy. CD24 is a glycosylphosphatidylinositol-anchored membrane protein with a small protein core and a high level of glycosylation. It is overexpressed in many human carcinomas and is correlated with poor prognosis. CD24 is a marker for pancreatic and ovarian cancer stem cells, whereas breast cancer stem cells are negative for CD24. In cancer cell lines, changes of CD24 expression can alter cellular properties in vitro and tumour growth in vivo. We have shown before that monotherapy with monoclonal antibody (mAb) SWA11 to CD24 effectively retarded tumour growth in xenotransplanted mice. Methods: Here, we have investigated in more detail the molecular mechanisms of mAb SWA11 therapeutic effects in A549 lung and SKOV3ip ovarian carcinoma models in scid/beige and CD1 mice, respectively. We focused on anti-proliferative, pro-apoptotic, anti-angiogenic and microenvironmental effects of SWA11 mAb treatment. Results: We find that CD24 targeting is associated with changes in tumour cell proliferation and angiogenesis. The treatment lead to increased infiltration of tumour tissues with immune cells suggesting involvement of ADCC. We found that SWA11 mAb treatment strongly altered the intratumoural cytokine microenvironment. The addition of SWA11 mAb to gemcitabine treatment strongly potentiated its anti-cancer efficacy in A549 lung cancer model. Conclusion: Our data demonstrate that targeting of CD24 could be beneficial for the anti-cancer treatment combined with standard chemotherapy regimes.
Collapse
Affiliation(s)
- A V Salnikov
- Department of Translational Immunology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Marme F, Schneeweiss A, Aigner J, Eidt S, Altevogt P, Sinn P, Wirtz RM. Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-06-08] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pathologic complete response (pCR, ypT0/is) is one of the strongest prognostic factors for primary breast cancer (PBC) in the setting of neoadjuvant chemotherapy (NAC). Factors predictive for response to NAC can help to stratify for an individualized therapy. As chemotherapeutic agents are most active in highly proliferative tumors, it was the aim of the present study to evaluate the potential of Ki-67 as a single proliferation marker, quantitatively measured on the mRNA or protein level, to predict response of PBC to NAC.
Material and methods: Pretreatment core cut biopsies from n=72 patients with PBC treated within a randomized phase II trial (1) of anthracylin/taxane based NAC were examined. Immunohistochemistry was performed for the Ki67 antigen on an automated IHC platform (Dako Techmate 500). Ki-67 were assessed either by visual scoring (vIHC) or by quantitative image analysis (qIHC). For quantitative IHC analysis tumor proliferation was analyzed after tumor stroma segmentation using the Aperio Image Analysis toolbox. RNA was extracted from formalin-fixed, paraffin embedded (FFPE) routine biopsies using a bead-based extraction method (STRATIFYER XTRAKT kits). Ki-67, TOP2A and RACGAP1 as well as CALM2 as a house keeping gene were measured via a multiplex quantitative RT-PCR (qPCR). Kaplan-Meier survival estimates, patitioning test and correlation analyses were performed using the SAS JMP® 9.0.0 software.
Results: There was only a moderate correlation between Ki-67 mRNA or Ki-67 measured by immunohistochemistry (IHC) and histologic grade (Spearman r = 0.52 p < 0.0001; r = 0.23 p = 0.033, respectively). Conventional visual scoring and qIHC correlated well (r = 0,78 p < 0,0001), while qPCR and qIHC correlated moderately (r = 0,50 p < 0,0001). For Ki-67 determined by visual scoring of standard IHC there was an optimal discrimination at a cut-off of 20% stained nuclei with regard to chemotherapy response. Yet, the difference between pCR-rates for high and low Ki-67 on IHC was non-significant, with 16.3% and 12.5% pCRs in the IHC Ki-67 high and low group, respectively. For Ki-67 IHC analysed by quantitative image analysis there was optimal cut-off at 35% stained nuclei resulting in 37,5% versus 8,7% pCR rate and 54% of pCRs classified correctly. For qPCR determination, high Ki-67 mRNA expression was associated with a high pCR-rate of 36.4% as opposed to 5.8% in tumors with low Ki-67 mRNA levels and 82% classified correctly.
Conclusion: High Ki-67 mRNA expression measured by RT-qPCR was predictive for the achievement of pCR to NAC and in this respect was superior to Ki-67 determined by vIHC or qIHC. This is consistent with data on Ki-67 IHC as a predictor of pCR on larger neoadjuvant cohorts (1). RT-qPCR based measurements of Ki-67 mRNA ensures an objective and highly reproducible quantification of proliferative activity from FFPE tissue from routine core cut biopsies. As such it seems to be more robust and meaningful compared to protein-based determination of Ki-67 by IHC, both by visual scoring or quantitative image analysis.
1) Schneeweiss et al, Ann Oncol 2011 2) Fasching et al., BMC Cancer 2011
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-06-08.
Collapse
Affiliation(s)
- F Marme
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - A Schneeweiss
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - J Aigner
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - S Eidt
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - P Altevogt
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - P Sinn
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - RM Wirtz
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| |
Collapse
|
8
|
Jurianz K, Haas C, Hubbe M, Ertel C, Brunner G, Altevogt P, Schirrmacher V, Vonhoegen P. Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction. Int J Oncol 2012; 7:539-45. [PMID: 21552872 DOI: 10.3892/ijo.7.3.539] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Infection of metastatic lymphoma cells (ESbL) by a low dose of a non-lytic strain of Newcastle disease virus (NDV) leads to viral replication followed by strong cell surface expression of viral antigens, especially hemagglutinin neuraminidase (HN). The expressed HN was functional and facilitated cell-cell interactions and cell attachment. This was shown for NDV infected tumor cells, lymphocytes, fibroblasts and endothelial cells. The interactions could be strongly inhibited by antibodies against the viral HN protein. Increased binding was also seen with HN c-DNA transfectants expressing the HN as the only viral protein. Viral infection did not influence proliferation and lysability of the infected tumor cells. Following intravenous injection of tumor cells, the number of hepatic metastases was significantly reduced when the cells had been pre-infected with NDV. This reduction of metastases correlated with an increased survival time of the animals. As potential mechanisms of these NDV effects we propose augmentation of cell-eel interactions and immune functions and reduction of invasive capacity of NDV infected, as compared to non-infected tumor cells.
Collapse
Affiliation(s)
- K Jurianz
- SMITHKLINE BEECHAM BIOL SA,R&D IMMUNOL BIOL,B-1330 RIXENSART,BELGIUM. DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV TUMOR IMMUNOL 0710,D-69120 HEIDELBERG,GERMANY
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Ann Oncol 2012; 23:1795-802. [PMID: 22228447 DOI: 10.1093/annonc/mdr568] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Overexpression of L1-cell adhesion molecule (L1CAM) has been observed for various carcinomas and correlates with poor prognosis and late-stage disease. In vitro, L1CAM enhances proliferation, cell migration, adhesion and chemoresistance. We tested L1CAM and interleukin-1 beta (IL-1β) expression in tumor samples and ascitic fluid from ovarian carcinoma patients to examine its role as a prognostic marker. PATIENTS AND METHODS We investigated tumor samples and ascitic fluid from 232 serous ovarian carcinoma patients for L1CAM by enzyme-linked immunosorbent assay. L1CAM expression was correlated with pathoclinical parameters and patients' outcome. IL-1β levels were measured in tumor cell lysates. Ovarian cancer cell lines were analyzed for the contribution of L1CAM to IL-1β production and nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) activation. RESULTS We observed that L1CAM-expressing tumors show a highly invasive phenotype associated with restricted tumor resectability at primary debulking surgery and increased lymphogenic spread. Soluble L1CAM proved to be a marker for poor progression-free survival and chemoresistance. In ovarian carcinoma cell lines, the specific knock-down of L1CAM reduces IL-1β expression and NF-κB activity. CONCLUSIONS L1CAM expression contributes to the invasive and metastatic phenotype of serous ovarian carcinoma. L1CAM expression and shedding in the tumor microenvironment could contribute to enhanced invasion and tumor progression through increased IL-1β production and NF-κB activation.
Collapse
Affiliation(s)
- S Bondong
- Department of Translational Immunology, German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Marmé F, Sohn C, Schneeweiss A, Altevogt P. Funktionelle, immunmodulatorische Polymorphismen im TLR-4 Rezeptor und prurinergen Rezeptor P2RX7 und ihr prädiktives Potential im Rahmen einer anthrazyklin- und taxan-basierten neoadjuvanten Chemotherapie bei primärem Mammakarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
11
|
Finas D, Köster F, Altevogt P, Hornung D. Therapie der Endometriose durch anti-L1CAM mAb im Mausmodell. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
12
|
Reimer D, Kiefel H, Hubalek M, Erdel M, Concin N, Hofstetter G, Mueller-Holzner E, Altevogt P, Marth C, Zeimet AG. Epidermal growth factor-mediated signaling in ovarian cancer and the role of miR-34a and 6p22 gene amplification-based E2F3a control. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Zeimet AG, Abdel-Azim S, Reimer D, Mueller-Holzner E, Winterhoff B, Puistola U, Ben-Arie A, vanKempen L, Amant F, Petru E, Jahn S, Polterauer S, Oppelt P, Weigert M, Altevogt P, Huszar M, Marth C, Fogel M. Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Reimer D, Kiefel H, Erdel M, Müller-Holzner E, Fiegl H, Marth C, Altevogt P, Zeimet AG. 6p22-Genamplifikation und Methylierung des miR-34a Promoters, zwei EGF-R unabhängige Mechanismen der E2F3a-Regulation beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
15
|
Edgar DH, de Graaff AA, D'Hooghe TM, Dunselman GAJ, Dirksen CD, Hummelshoj L, EndoCost Consortium WERF, Simoens S, Garcia-Cerrudo E, Martinez-Conejero JA, Herrero L, Rodriguez S, Horcajadas JA, Remohi J, Garcia-Velasco JA, Salker MS, Christian M, Steel JH, Nautiyal J, Lang F, Brosens JJ, Mitra A, Bhattacharya J, Kundu S, Pal M, Mukhopadhyay D, Komsky A, Ben-Ami I, Strassburger D, Kasterstein E, Komarovsky D, Bern O, Maslansky B, Raziel A, Friedler S, Gidoni YS, Ron-El R, Finas D, Hunold P, Koester F, Altevogt P, Hornung D. SELECTED ORAL COMMUNICATION SESSION, SESSION 62: ENDOMETRIUM, IMPLANTATION AND ENDOMETRIOSIS Wednesday 6 July 2011 10:00 - 11:45. Hum Reprod 2011. [DOI: 10.1093/humrep/26.s1.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Machado E, Kandzia S, Carilho R, Altevogt P, Conradt HS, Costa J. N-Glycosylation of total cellular glycoproteins from the human ovarian carcinoma SKOV3 cell line and of recombinantly expressed human erythropoietin. Glycobiology 2010; 21:376-86. [DOI: 10.1093/glycob/cwq170] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Sebens S, Geismann C, Egberts J, Korniyenko L, Kalthoff H, Leisner D, Tsao M, Moldenhauer G, Altevogt P, Schäfer H. 865 Elevated L1CAM expression mediates malignant transformation and enhances tumourigenicity of pancreatic ductal epithelial cells. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71659-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
18
|
Marme F, Werft W, Benner A, Burwinkel B, Sinn H, Sohn C, Lichter P, Hahn M, Altevogt P, Schneeweiss A. Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Müller-Holzner E, Fiegl H, Marth C, Altevogt P, Zeimet AG. Molekulare Grundlage und Funktion der EGF-E2F3a Achse in der Tumorbiologie des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 2010. [DOI: 10.1055/s-0030-1252096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
20
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG. Die Bedeutung von E2F3a in der EGFR vermittelten Proliferation im Ovarialkarzinom – Biologische und klinische Relevanz. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1239005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
21
|
Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov AV, Herr I. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009; 58:949-63. [PMID: 18829980 DOI: 10.1136/gut.2008.149039] [Citation(s) in RCA: 169] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIMS Emerging evidence suggests that highly treatment-resistant tumour-initiating cells (TICs) play a central role in the pathogenesis of pancreatic cancer. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered to be a novel anticancer agent; however, recent studies have shown that many pancreatic cancer cells are resistant to apoptosis induction by TRAIL due to TRAIL-activated nuclear factor-kappaB (NF-kappaB) signalling. Several chemopreventive agents are able to inhibit NF-kappaB, and favourable results have been obtained--for example, for the broccoli compound sulforaphane-in preventing metastasis in clinical studies. The aim of the study was to identify TICs in pancreatic carcinoma for analysis of resistance mechanisms and for definition of sensitising agents. METHODS TICs were defined by expression patterns of a CD44(+)/CD24(-), CD44(+)/CD24(+) or CD44(+)/CD133(+) phenotype and correlation to growth in immunodeficient mice, differentiation grade, clonogenic growth, sphere formation, aldehyde dehydrogenase (ALDH) activity and therapy resistance. RESULTS Mechanistically, specific binding of transcriptionally active cRel-containing NF-kappaB complexes in TICs was observed. Sulforaphane prevented NF-kappaB binding, downregulated apoptosis inhibitors and induced apoptosis, together with prevention of clonogenicity. Gemcitabine, the chemopreventive agents resveratrol and wogonin, and the death ligand TRAIL were less effective. In a xenograft model, sulforaphane strongly blocked tumour growth and angiogenesis, while combination with TRAIL had an additive effect without obvious cytotoxicity in normal cells. Freshly isolated patient tumour cells expressing markers for TICs could be sensitised by sulforaphane for TRAIL-induced cytotoxicity. CONCLUSION The data provide new insights into resistance mechanisms of TICs and suggest the combination of sulforaphane with TRAIL as a promising strategy for targeting of pancreatic TICs.
Collapse
Affiliation(s)
- G Kallifatidis
- Molecular OncoSurgery Group, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Mueller-Holzner E, Marth C, Altevogt P, Zeimet AG. Regulation of the EGFR-E2F3a axis by the interferon regulatory factor (IRFs) and by promoter methylation of miR-34a in ovarian cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16522 Background: Although, EGFR targeting has reached “bedside” in various tumor entities, including ovarian cancer, the essential role of E2F3a in EGFR mediated proliferation remained uncovered. Recently, we outlined the clinical relevance of E2F3a in ovarian cancer. Now we were able to elucidate the pathway between EGFR activation and E2F3a induction. Methods: Promoter mapping of E2F family members was assessed using the JASPER software. E2F3a protein was assessed by immunoblot analyses in siRNA based IRF-1, IRF-2 knockdown HOC-7 cells. Cell growth was determined by MTT assays after siRNA based knockdown of E2F3a. Expression of E2F3a regulating miR-34a, miR-210 and miR-20a were assessed by RT-PCR in 130 ovarian cancer patients and methylation status of the E2F3a promoter and of miRNA promoters were estimated using Methyllight. 6p22 amplification status of patients was determined by FISH analyses. Results: Promoter mapping of E2F family members revealed that IRF-1 and IRF-2 are potential intermediate components of the herein described EGFR-E2F3a axis. As evidenced by knock-down of IRF-1, IRF-2 or both, the ratio between the two mutually antagonistic IRF-1 and IRF-2 was found to be substantial for EGF induced E2F3a up-regulation. E2F3a knock-down yielded a complete abolishment of EGF induced cancer cell proliferation. Although, activated EGFR status showed a highly significant correlation with E2F3a expression, a subgroup of patients presented high E2F3a mRNA levels without EGFR activation. Within this subgroup promoter methylation of miRNA-34a, that regulates E2F3a, was revealed to represent an alternative mechanism of E2F3a regulation in ovarian cancer, whereas promoter methylation of E2F3a itself was not relevant in E2F3a control. Unlike in prostate or bladder cancer 6p22 amplification was not found to be relevant for E2F3a up-regulation in ovarian cancer. Conclusions: Our present data point to the substantial role of the ratio between IRF-1 and IRF-2 in EGFR mediated E2F3a induction. Furthermore, in vivo regulation of E2F3a involves methylation and thereby silencing of miR-34a. Targeting of the herein described molecular pathway, downstream EGFR, could represent an appealing therapeutic approach in ovarian cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Reimer
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - M. Hubalek
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - S. Riedle
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - S. Skvortsov
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - M. Erdel
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - E. Mueller-Holzner
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - C. Marth
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - P. Altevogt
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - A. G. Zeimet
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| |
Collapse
|
23
|
Sebens S, Geismann C, Morscheck M, Koch D, Ungefroren H, Arlt A, Tsao M, Bachem M, Altevogt P, Schäfer H. 346 POSTER Myofibroblasts and TGF-beta1 induce upregulation of tumoral L1CAM thereby promoting malignant transformation of pancreatic ductal epithelial cells. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72280-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
24
|
Hörzer H, Marmé A, Stevanovic S, Altevogt P, Wallwiener D, Gückel B. Entwicklung einer Peptid-basierten Vakzine gegen Antigene des Ovarialkarzinoms (OvCa) und dessen tumorassoziiertem Endothel – Präklinische Studie. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1089311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
25
|
Finas D, Huszar M, Agic A, Dogan S, Kiefel H, Riedle S, Gast D, Marcovich R, Noack F, Altevogt P, Fogel M, Hornung D. L1 cell adhesion molecule (L1CAM) as a pathogenetic factor in endometriosis. Hum Reprod 2008; 23:1053-62. [DOI: 10.1093/humrep/den044] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
26
|
Ben-Arie A, Huszar M, Ben-Zvi N, Smirnov A, Altevogt P, Fogel M. The role of L1-CAM immunohistochemial staining in the diagnosis of abdominal-pelvic cancer of uncertain primary site in women. Eur J Surg Oncol 2007; 34:795-9. [PMID: 17845837 DOI: 10.1016/j.ejso.2007.07.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2007] [Accepted: 07/16/2007] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE The L1 adhesion molecule (L1-CAM,CD171) is over expressed in ovarian and endometrial carcinomas and other tumors derived from the Mullerian tract. Here we evaluated whether L1-CAM could serve as a novel tumor marker for the diagnosis of metastatic abdominal-pelvic cancers of uncertain origin in women. PATIENTS AND METHODS During a 6-year period we investigated 28 patients with metastatic abdominal or pelvic cancer with uncertain primary-origin. In all these cases a thorough clinical, surgical, pathologic and immunohistochemistry evaluation was performed and correlated to the L1-CAM expression as determined by immunohistochemical staining. RESULTS In 20 patients where the differential diagnosis was primary ovarian or endometrial cancer and primary or recurrent colon cancer, L1 immunohistochemistry staining allowed or supported the correct diagnosis. In four cases L1 staining allowed the correct diagnosis between breast and ovarian cancer. In two cases vaginal metastases of unknown origin were positive to L1 immunohistochemistry staining implying their mullerian origin and one case each of inguinal lymph node metastases and abdominal wall cancer that were positive for L1-CAM, allowed the correct diagnosis of primary ovarian cancer. In a whole, L1-CAM was of crucial role of delinating the final diagnosis in 17 of the 28 cases described. CONCLUSIONS L1-CAM, a new tumor marker, was found to be specific for metastatic cancer originating from mullerian origin. Its incorporation into the conventional immunohistochemistry analysis in cases of cancer of unknown primary in women, allows a correct diagnosis and subsequent treatment in the majority of cases with abdominal-pelvic carcinomatosis.
Collapse
Affiliation(s)
- A Ben-Arie
- Department of Gynecology-Oncology, Kaplan Medical Center, 76100 Rehovot, Israel.
| | | | | | | | | | | |
Collapse
|
27
|
Agic A, Finas D, Djalali S, Dogan S, Diedrich K, Altevogt P, Hornung D. Neuronales Wachstum und Zellinvasion im Endometriosemodell durch Stimulation mit L1CAM (CD171). Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-989140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
28
|
Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, Hager HD, Abdel-Bakky MS, Gutwein P, Altevogt P. CD24 is a marker of exosomes secreted into urine and amniotic fluid. Kidney Int 2007; 72:1095-102. [PMID: 17700640 DOI: 10.1038/sj.ki.5002486] [Citation(s) in RCA: 265] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Exosomes are small membrane vesicles that are secreted from a variety of cell types into various body fluids including the blood and urine. These vesicles are thought to play a role in cell-cell interactions. CD24 is a small but extensively glycosylated protein linked to the cell surface by means of a glycosyl-phosphatidylinositol anchor. In this study we found that CD24 is present in membrane vesicles characterized as exosomes that were isolated from the urine of normal individuals. CD24 was expressed by both tubule cells and podocytes and treatment of the latter with a cholesterol-extracting agent, but not with a calcium ionophore, caused the release of CD24-containing exosomes. Using CD24 as a marker, we found exosomes in the urine of newborn infants and in the amniotic fluid of pregnant women with similar findings made in mice. Interestingly, studies with CD24 knockout mice showed that the exosomes are released from the fetus but not from the mother; however, exosome release was similar from both the knockout and the wild-type mice. This indicates that CD24 is not essential for exosome formation or release but may be a convenient exosome marker. Our studies suggest that exosomal secretion from the embryonic kidney could play a biological role at the fetal-maternal interphase.
Collapse
Affiliation(s)
- S Keller
- Tumor Immunology Programme, German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sebens Müerköster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, Leisner D, Kötteritzsch J, Kappes H, Klöppel G, Altevogt P, Fölsch UR, Schäfer H. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2006; 26:2759-68. [PMID: 17086212 DOI: 10.1038/sj.onc.1210076] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by rapid tumor progression, high metastatic potential and profound chemoresistance. We recently reported that induction of a chemoresistant phenotype in the PDAC cell line PT45-P1 by long-term chemotherapy involves an increased interleukin 1 beta (IL1beta)-dependent secretion of nitric oxide (NO) accounting for efficient caspase inhibition. In the present study, we elucidated the involvement of L1CAM, an adhesion molecule previously found in other malignancies, in this NO-dependent chemoresistance. Chemoresistant PT45-P1res cells, but not chemosensitive parental PT45-P1 cells, express high levels of L1CAM in an ILbeta-dependent fashion. PT45-P1res cells subjected to short interfering RNA (siRNA)-mediated L1CAM knock-down exhibited reduced inducible nitric oxide synthase expression and NO secretion, as well as a significant increase of anti-cancer drug-induced caspase activation, an effect reversed by the NO donor S-nitroso-N-acetyl-D,L-penicillamine. Conversely, overexpression of L1CAM in PT45-P1 cells conferred anti-apoptotic protection to anti-cancer drug treatment. Interestingly, L1CAM ectodomain shedding, in example, by ADAM10, as reported for other L1CAM-related activities, seemed to be dispensable for anti-apoptotic protection by L1CAM. Neither the shedded L1CAM ectodomain was detected in chemoresistant L1CAM-expressing PT45-P1 cells nor did the administration of various metalloproteinase inhibitors affect L1CAM-dependent chemoresistance. Immunohistochemical analysis revealed L1CAM expression in 80% of pancreatic cancer specimens, supporting a potential role of L1CAM in the malignancy of this tumor. These findings substantiate our understanding of the molecular mechanisms leading to chemoresistance in PDAC cells and indicate the importance of L1CAM in this scenario.
Collapse
Affiliation(s)
- S Sebens Müerköster
- Clinic of Internal Medicine, Laboratory of Molecular Gastroenterology and Hepatology, UKSH-Campus Kiel, Kiel, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Finas D, Agic A, Altevogt P, Fogel M, Diedrich K, Hornung D, Dogan S. Das neuonaleZelladhäsionsmolekül L1 bei Endometriose. Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
Escrevente C, Machado E, Brito C, Reis CA, Stoeck A, Runz S, Marmé A, Altevogt P, Costa J. Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. Int J Oncol 2006; 29:557-66. [PMID: 16865271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023] Open
Abstract
Ovarian carcinoma is the leading cause of death from gynecological cancers in many countries. Fucosylated glycoconjugates have been associated with various carcinomas. In the present study, we have characterized the expression of alpha3/4 fucosyltransferases transcripts and their products, the Lewis carbohydrate determinants, and their in vitro specificity towards synthetic acceptors using ovarian carcinoma cell lines OVM, m130, GG and SKOV3. We found different expression patterns: GG cells expressed mostly Lewisx (Lex), Lewisy (Ley), sLea and Leb, and m130 cells expressed mostly Lex and Ley. The detection was on the plasma membrane and in intracellular vesicles. OVM and SKOV3 cells had very low amounts of staining. From RT-PCR studies, enzyme specificity of cellular extracts towards a panel of synthetic carbohydrate acceptors and Western blot analysis we concluded that Lea, sLea and Leb were synthesised by FUT3, whereas Lex and Ley were synthesized by FUT4 and FUT9 in both cell lines. The GG and m130 cell lines are adequate models to investigate the role of Lex, Ley, sLea and Leb in ovarian carcinoma development.
Collapse
MESH Headings
- Adenocarcinoma, Mucinous/genetics
- Adenocarcinoma, Mucinous/metabolism
- Adenocarcinoma, Mucinous/pathology
- Blotting, Western
- Carcinoma, Papillary/genetics
- Carcinoma, Papillary/metabolism
- Carcinoma, Papillary/pathology
- Cystadenocarcinoma, Serous/genetics
- Cystadenocarcinoma, Serous/metabolism
- Cystadenocarcinoma, Serous/pathology
- Female
- Fucose/metabolism
- Fucosyltransferases/genetics
- Fucosyltransferases/metabolism
- Gene Expression Regulation, Neoplastic
- Humans
- Lectins/metabolism
- Lewis Blood Group Antigens/genetics
- Lewis Blood Group Antigens/metabolism
- Microscopy, Fluorescence
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/metabolism
- Ovarian Neoplasms/pathology
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- C Escrevente
- Instituto de Tecnologia Química e Biológica, 2781-901 Oeiras, Portugal
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Escrevente C, Machado E, Brito C, Reis C, Stoeck A, Runz S, Marmé A, Altevogt P, Costa J. Different expression levels of α3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. Int J Oncol 2006. [DOI: 10.3892/ijo.29.3.557] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
33
|
Abstract
CD24 is a molecule that recently has raised considerable attention in tumour biology. It is involved in cell adhesion and metastatic tumour spread. It has also been described as a new diagnostic marker of tumours, of neuroendocrine differentiation and, possibly most intriguing of all, of patient prognosis. High rates of CD24 expression detected by immunohistochemistry have been found in epithelial ovarian cancer (83%), breast cancer (85%), non-small cell lung cancer (45%), prostate cancer (48%) and pancreatic cancer (72%). With the exception of pancreatic cancer, high rates of CD24 are significantly associated with a more aggressive course of the disease, a finding that remains significant in a multivariate analysis. The aim of this review is to summarize relevant work covering these aspects of CD24.
Collapse
Affiliation(s)
- G Kristiansen
- Institute of Pathology, Charité University Hospital, Schumannstrasse 20/21, 10117 Berlin, Germany
| | | | | |
Collapse
|
34
|
Abstract
CD24 is a molecule that recently has raised considerable attention in tumour biology. It is involved in cell adhesion and metastatic tumour spread. It has also been described as a new diagnostic marker of tumours, of neuroendocrine differentiation and, possibly most intriguing of all, of patient prognosis. High rates of CD24 expression detected by immunohistochemistry have been found in epithelial ovarian cancer (83%), breast cancer (85%), non-small cell lung cancer (45%), prostate cancer (48%) and pancreatic cancer (72%). With the exception of pancreatic cancer, high rates of CD24 are significantly associated with a more aggressive course of the disease, a finding that remains significant in a multivariate analysis. The aim of this review is to summarize relevant work covering these aspects of CD24.
Collapse
Affiliation(s)
- G Kristiansen
- Institute of Pathology, Charité University Hospital, Schumannstrasse 20/21, 10117 Berlin, Germany
| | | | | |
Collapse
|
35
|
|
36
|
Abstract
The L1 molecule has recently emerged as a promising new biomarker for the prognosis of human ovarian and endometrial tumors. It was initially described as an adhesion molecule for the development of the nervous system but its function in tumor cells is not well known. In this article we summarize recent data on the role of L1 in promoting tumor cell adhesion and migration and in gene regulation. We address the question how L1 determination in tumor tissue samples and in serum and ascites could potentially improve the disease management.
Collapse
Affiliation(s)
- P Altevogt
- Tumor Immunology Programme, D010, German Cancer Research Center, Heidelberg, Germany.
| | | |
Collapse
|
37
|
Kristiansen G, Kaiser S, Pilarsky C, Dahl E, Winzer K, Denkert C, Stephan C, Jung K, Guski H, Petersen I, Hauptmann S, Rosenthal A, Altevogt P, Dietel M. Differentially expressed genes in prostate cancer — identification of CD24 as a new prognostic marker. Pathol Res Pract 2004. [DOI: 10.1016/s0344-0338(04)80436-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Abstract
N-glycans of the mouse glycoprotein HSA and its human analogue CD24 from lymphoblastoma, neuroblastoma and astrocytoma cell lines as well as from mouse brain homogenate were analysed and compared to each other and to the N-glycosylation pattern of total glycoproteins from mouse and human brain. The N-glycans were released from PVDF-blotted HSA or CD24 and separated on Carbograph SPE into neutral and acid glycans. The naturally neutral glycan fraction and the fraction of glycans rendered neutral after neuraminidase treatment were analysed without further purification by MALDI-MS. In each fraction, about 25 molecular ions with an intensity >10% of the base peak were identified which corresponded to glycans with distinct isobaric monosaccharide compositions. Comparison of the neutral and desialylated glycans revealed some similarities between the samples analysed, but also clear differences. HSA and CD24 from all cell lines express almost no neutral N-glycans with two or more fucose in contrast to brain HSA and glycoproteins from mouse and human brain. The lack of extensive fucosylation was also observed for desialylated glycans of HSA and CD24 from all cell lines analysed except for CD24 from a human neuroblastoma cell line which exhibits like total human and mouse brain glycoproteins a large variety of highly fucosylated, higher branched N-glycans. HSA from mouse brain carries in addition desialylated non-fucosylated glycans of high abundance which were detected, if at all, only at low intensity in all other samples analysed suggesting that they may be implicated in specific functions of mouse brain HSA. Therefore, a rapid assessment of similarities or differences between glycosylation patterns of a glycoprotein isolated from different sources is possible using methods as described here.
Collapse
Affiliation(s)
- C Ohl
- Institute of Physiology, Biochemistry and Animal Health, University of Bonn, Katzenburgweg 9a, 53115 Bonn, Germany
| | | | | | | |
Collapse
|
39
|
Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, Altevogt P. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001; 155:661-73. [PMID: 11706054 PMCID: PMC2198870 DOI: 10.1083/jcb.200101099] [Citation(s) in RCA: 304] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The L1 adhesion molecule plays an important role in axon guidance and cell migration in the nervous system. L1 is also expressed by many human carcinomas. In addition to cell surface expression, the L1 ectodomain can be released by a metalloproteinase, but the biological function of this process is unknown. Here we demonstrate that membrane-proximal cleavage of L1 can be detected in tumors and in the developing mouse brain. The shedding of L1 involved a disintegrin and metalloproteinase (ADAM)10, as transfection with dominant-negative ADAM10 completely abolishes L1 release. L1-transfected CHO cells (L1-CHO) showed enhanced haptotactic migration on fibronectin and laminin, which was blocked by antibodies to alpha v beta 5 and L1. Migration of L1-CHO cells, but not the basal migration of CHO cells, was blocked by a metalloproteinase inhibitor, indicating a role for L1 shedding in the migration process. CHO and metalloproteinase-inhibited L1-CHO cells were stimulated to migrate by soluble L1-Fc protein. The induction of migration was blocked by alpha v beta 5-specific antibodies and required Arg-Gly-Asp sites in L1. A 150-kD L1 fragment released by plasmin could also stimulate CHO cell migration. We propose that ectodomain-released L1 promotes migration by autocrine/paracrine stimulation via alpha v beta 5. This regulatory loop could be relevant for migratory processes under physiological and pathophysiological conditions.
Collapse
Affiliation(s)
- S Mechtersheimer
- Tumor Immunology Program, G0100, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
A characteristic feature of integrin-ligand interactions is the requirement for divalent cations. Putative cation binding sites have been identified in the alpha and beta subunit of the alpha4 integrins, alpha4beta1 and alpha4beta7, and within their ligands which display the tripeptide LDV in fibronectin and homologous motifs in VCAM-1 and MAdCAM-1. The extracellular domain of the murine and human alpha4-subunit contains three conserved LDV motifs, designated LDV-1 to -3. Using site directed mutagenesis and transfection studies, we now examined the functional relevance of the LDV motifs for alpha4beta7 integrins. We present evidence that LDV-1 mutants (D489N) behave like alpha4 wt cells, but LDV-3 mutants (D811N) are impaired in alpha4beta7 integrin-triggered homotypic cell aggregation and in adhesion and spreading on alpha4 specific ligands. Further characterization of LDV-3 mutants revealed a defect in mAb-induced alpha4beta7-cell surface cluster formation. Mutation of the LDV-2 motif (D698N) caused loss of alpha4beta7 integrin cell surface expression. Our results indicate: (i) that LDV-3, located proximal to the cell membrane, is important for alpha4beta7 integrin-triggered functions and for lateral clustering and (ii) that LDV-2 affects alpha4beta7 heterodimer stability.
Collapse
Affiliation(s)
- Y Zeller
- Tumor Immunology Programme, G0100, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | | | |
Collapse
|
41
|
Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 2001; 276:10952-62. [PMID: 11278329 DOI: 10.1074/jbc.m007027200] [Citation(s) in RCA: 122] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The first prototype of the protease activated receptor (PAR) family, the thrombin receptor PAR1, plays a central role both in the malignant invasion process of breast carcinoma metastasis and in the physiological process of placental implantation. The molecular mechanism underlying PAR1 involvement in tumor invasion and metastasis, however, is poorly defined. Here we show that PAR1 increases the invasive properties of tumor cells primarily by increased adhesion to extracellular matrix components. This preferential adhesion is accompanied by the cytoskeletal reorganization of F-actin toward migration-favoring morphology as detected by phalloidin staining. Activation of PAR1 increased the phosphorylation of focal adhesion kinase and paxillin, and the induced formation of focal contact complexes. PAR1 activation affected integrin cell-surface distribution without altering their level of expression. The specific recruitment of alpha(v)beta(5) to focal contact sites, but not of alpha(v)beta(3) or alpha(5)beta(1), was observed by immunofluorescent microscopy. PAR1 overexpressing cells showed selective reciprocal co-precipitation with alpha(v)beta(5) and paxillin but not with alpha(v)beta(3) that remained evenly distributed under these conditions. This co-immunoprecipitation failed to occur in cells containing the truncated form of PAR1 that lacked the entire cytoplasmic portion of the receptor. Thus, the PAR1 cytoplasmic tail is essential for conveying the cross-talk and recruiting the alpha(v)beta(5) integrin. While PAR1 overexpressing cells were invasive in vitro, as reflected by their migration through a Matrigel barrier, invasion was further enhanced by ligand activation of PAR1. Moreover, the application of anti-alpha(v)beta(5) antibodies specifically attenuated this PAR1 induced invasion. We propose that the activation of PAR1 may lead to a novel cooperation with the alpha(v)beta(5) integrin that supports tumor cell invasion.
Collapse
Affiliation(s)
- S C Even-Ram
- Departments of Oncology and Pharmacology at the Hadassah-Hebrew University Hospital, Jerusalem 91120, Israel, the Department of Hematology, Medical Center, Tel Aviv 64239, Israel
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Friederichs J, Zeller Y, Hafezi-Moghadam A, Gröne HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000; 60:6714-22. [PMID: 11118057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Carbohydrates on tumor cells have been shown to play an important role in tumor metastasis. We demonstrated before that CD24, a Mr 35,000-60,000 mucine-type glycosylphosphatidylinositol-linked cell surface molecule, can function as ligand for P-selectin and that the sialylLex carbohydrate is essential for CD24-mediated rolling of tumor cells on P-selectin. To investigate the role of both antigens more closely, we transfected human A125 adenocarcinoma cells with CD24 and/or fucosyltransferase VII (Fuc TVII) cDNAs. Stable transfectants expressed CD24 and/or sialylLex. Biochemical analysis confirmed that in A125-CD24/FucTVII double transfectants, CD24 was modified with sialylLex. Only double transfectants showed rolling on P-selectin in vivo. When injected into mice, double transfectants arrested in the lungs, and this step was P-selectin dependent because it was strongly enhanced in lipopolysaccharide (LPS) pretreated wild-type mice but not in P-selectin knockout mice. CD24 modified by sialylLex was required on the tumor cells because the LPS-induced lung arrest was abolished by removal of CD24 from the cell surface by phosphatidylinositol-specific phospholipase C. A125-FucTVII single transfectants expressing sialylLex but not CD24 did not show P-selectin-mediated lung arrest. The sialylLex epitope is abundantly expressed on human carcinomas, and significant correlations between sialylLex expression and clinical prognosis exist. Our data suggest an important role for sialylLex-modified CD24 in the lung colonization of human tumors.
Collapse
Affiliation(s)
- J Friederichs
- Tumor Immunology Programme, German Cancer Research Center, Heidelberg
| | | | | | | | | | | |
Collapse
|
43
|
Oleszewski M, Gutwein P, von der Lieth W, Rauch U, Altevogt P. Characterization of the L1-neurocan-binding site. Implications for L1-L1 homophilic binding. J Biol Chem 2000; 275:34478-85. [PMID: 10934197 DOI: 10.1074/jbc.m004147200] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The L1 adhesion molecule is a 200-220-kDa membrane glycoprotein of the Ig superfamily implicated in important neural processes including neuronal cell migration, axon outgrowth, learning, and memory formation. L1 supports homophilic L1-L1 binding that involves several Ig domains but can also bind with high affinity to the proteoglycan neurocan. It has been reported that neurocan can block homophilic binding; however, the mechanism of inhibition and the precise binding sites in both molecules have not been determined. By using fusion proteins, site-directed mutagenesis, and peptide blocking experiments, we have characterized the neurocan-binding site in the first Ig-like domain of human L1. Results from molecular modeling suggest that the sequences involved in neurocan binding are localized on the surface of the first Ig domain and largely overlap with the G-F-C beta-strands proposed to interact with the fourth Ig domain during homophilic binding. This suggests that neurocan may sterically hinder a proper alignment of L1 domains. We find that the C-terminal portion of neurocan is sufficient to mediate binding to the first Ig domain of L1, and we suggest that the sushi domain cooperates with a glycosaminoglycan side chain in forming the binding site for L1.
Collapse
Affiliation(s)
- M Oleszewski
- Tumor Immunology Programme, G0100, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | | | | | | | |
Collapse
|
44
|
Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K, Altevogt P. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000; 275:15490-7. [PMID: 10809781 DOI: 10.1074/jbc.275.20.15490] [Citation(s) in RCA: 153] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The ectodomain of certain transmembrane molecules can be released by proteolysis, and the solubilized antigens often exert important biological functions. We demonstrated before that the L1 adhesion molecule is shed from the cell surface. Here we show that L1 release in AR breast carcinoma cells is mediated by a member of the disintegrin metalloproteinase (ADAM) family of proteinases. Up-regulation of L1 shedding by phorbol ester or pervanadate involved distinct mechanisms. Pervanadate induced shedding and rounding-up of cells from the substrate, which was blocked by the Src kinase inhibitor PP2. Tyr phosphorylation of the L1 cytoplasmic tail and the Src kinase Fyn was observed following pervanadate treatment. Up-regulation of L1 release and activation of Fyn occurred also when cells were detached by EDTA suggesting that the regulation of L1 shedding by this pathway was linked to cell morphology and adhesion. The phorbol 12-myristate 13-acetate-induced shedding was inhibited by the protein kinase C inhibitor bisindolylmaleimide I and by PD98059, a specific inhibitor of the mitogen-activated protein kinase pathway. Soluble L1 binds to the proteoglycan neurocan and in bound form could support integrin-mediated cell adhesion and migration. We propose that the release of cell-associated adhesion molecules such as L1 may be relevant to promote cell migration.
Collapse
Affiliation(s)
- P Gutwein
- Tumor Immunology Programme, 0710, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
45
|
Abstract
The leukocyte function-associated antigen-1 (LFA-1) integrin (CD11a/CD18) is an important adhesion molecule for lymphocyte migration and the initiation of an immune response. At the cell surface, LFA-1 activity can be regulated by divalent cations that enhance receptor affinity but also by membrane clustering induced by treatment of cells with substances such as phorbol esters. Membrane clustering leads to increased LFA-1 avidity. We report here that LFA-1-mediated binding of mouse thymocytes or activated T lymphocytes to intercellular adhesion molecule 1 can be rapidly induced by clustering of membrane rafts using antibodies to the glycosylphophatidylinositol-anchored molecule CD24 or cholera toxin (CTx). CD24 and CD18 were found to co-localize in rafts and cross-linking with CTx lead to enhanced LFA-1 clustering. We observed that disruption of raft integrity by lowering the membrane cholesterol content abolished the CTx and the phorbol 12-myristate 13-acetate-induced LFA-1 binding but left the ability to activate LFA-1 with Mg(2+)/EGTA unimpaired. In contrast to activation with Mg(2+)/EGTA, activation via raft clustering was dependent on PI3-kinase, required cytoskeletal mobility, and was accompanied by Tyr phosphorylation of a 18-kDa protein. Our results support the notion that rafts as preformed adhesion platforms could be important for the rapid regulation of lymphocyte adhesion.
Collapse
Affiliation(s)
- K Krauss
- Tumor Immunology Programme, G0100, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | |
Collapse
|
46
|
Abstract
The cell adhesion molecule L1, a 200-220-kDa type I membrane glycoprotein of the Ig superfamily, mediates many neuronal processes. Originally studied in the nervous system, L1 is expressed by hematopoietic and many epithelial cells, suggesting a more expanded role. L1 supports homophilic L1-L1 and integrin-mediated cell binding and can also bind with high affinity to the neural proteoglycan neurocan; however, the binding site is unknown. We have dissected the L1 molecule and investigated the cell binding ability of Ig domains 1 and 6. We report that RGD sites in domain 6 support alpha5beta1- or alphavbeta3-mediated integrin binding and that both RGD sites are essential. Cooperation of RGD sites with neighboring domains are necessary for alpha(5)beta(1). A T cell hybridoma and activated T cells could bind to L1 in the absence of RGDs. This binding was supported by Ig domain 1 and mediated by cell surface-exposed neurocan. Lymphoid and brain-derived neurocan were structurally similar. We also present evidence that a fusion protein of the Ig 1-like domain of L1 can bind to recombinant neurocan. Our results support the notion that L1 provides distinct cell binding sites that may serve in cell-cell or cell-matrix interactions.
Collapse
Affiliation(s)
- M Oleszewski
- Tumor Immunology Programme, G0100, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
CD24 is a small, mucin-type glycosylphosphatidylinositol-linked cell surface molecule expressed by neutrophils, pre B lymphocytes and certain human tumor cell lines. CD24 has been identified as a ligand for P-selectin in both mouse and human cells. We previously reported that the P-selectin-CD24 binding pathway is important for the binding of the breast carcinoma cell line KS to platelets and the rolling of these cells on endothelial P-selectin. In the present study we have analyzed the expression of CD24 on human breast carcinoma cell lines and on fresh breast carcinoma specimens using the CD24-specific antibody ML-5. Our study clearly demonstrates that CD24 is abundantly expressed on cell lines and fresh tissues of breast carcinomas. We find a differential expression of CD24 in breast carcinomas (cytoplasmic pattern) versus benign breast lesions (apical pattern). Moreover, the intensity of CD24 expression increases with the histological grade of the tumor. Thus, CD24 expression might be a useful marker for human breast carcinoma and play a role in facilitating metastasis by the interaction between tumor cells and platelets or endothelial cells.
Collapse
MESH Headings
- Antibodies, Monoclonal
- Antigens, CD/analysis
- Biomarkers, Tumor/analysis
- Breast Neoplasms/chemistry
- Breast Neoplasms/pathology
- CD24 Antigen
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Intraductal, Noninfiltrating/chemistry
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Female
- Fibroadenoma/chemistry
- Fibroadenoma/pathology
- Fibrocystic Breast Disease/chemistry
- Fibrocystic Breast Disease/pathology
- Humans
- Immunoenzyme Techniques
- Membrane Glycoproteins
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- M Fogel
- Tumor Immunology Research Laboratory, Kaplan Hospital, Rehovot, Israel
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
The L1 adhesion molecule is an approx. 200–220 kDa type I membrane glycoprotein belonging to the immunoglobulin (Ig) superfamily. L1 can bind in a homotypic fashion and was shown to support integrin-mediated binding via RGDs in the 6th Ig-like domain. In addition to its cell-surface expression, L1 can occur in the extracellular matrix (ECM). Here we demonstrate that L1 is constitutively released from the cell surface by membrane-proximal cleavage. L1 shed from B16F10 melanoma cells remains intact and can serve as substrate for integrin-mediated cell adhesion and migration. The release of L1 occurs in mouse and human cells and is blocked by the metalloproteinase inhibitor TAPI (Immunex compound 3). This compound has been shown previously to block release of L-selectin and TNF-alpha which is mediated by the membrane-bound metalloproteinase TNF-alpha converting enzyme (TACE). Using CHO cells that are low in TACE expression and do not release L-selectin we demonstrate that L1 release is distinct from L-selectin shedding. We propose that cell-surface release may be necessary for the conversion of L1 from a membrane into an ECM protein.
Collapse
Affiliation(s)
- S Beer
- Tumor Immunology Programme, German Cancer Research Center, D-69120 Heidelberg, Germany
| | | | | | | | | |
Collapse
|
49
|
Abstract
P-selectin mediates rolling of neutrophils and other leukocytes on activated endothelial cells and platelets through binding to P-selectin glycoprotein ligand-1 (PSGL-1). Certain PSGL-1 negative tumor cell lines can bind P-selectin under static conditions through the GPI-linked surface mucin, CD24, but the physiological significance of this interaction and whether it can occur under flow conditions is not known. Here, we show that CD24+ PSGL-1- KS breast carcinoma cells attach to and roll on recombinant P-selectin under a continuous wall shear stress, although at a lower density and higher velocity than CD24+ PSGL-1+ cells, such as HL-60. Adding excess soluble CD24 or removing CD24 from the cell surface with phosphatidylinositol-phospholipase C (PI-PLC) significantly reduced KS cell rolling on P-selectin. The ability of KS cells to roll on P-selectin was positively correlated with the CD24 expression level. Comparison with three other CD24+ cell lines established that expression of sialyl-Lewis(x) antigen was also necessary for CD24-mediated rolling on P-selectin. CD24 purified from KS cells supported rolling of P-selectin transfectants, but not L-selectin transfectants. Finally, KS cells rolled on vascular endothelium in vivo in a P-selectin-dependent manner. Together our data show that CD24 serves as a ligand for P-selectin under physiological flow conditions. Interaction of tumor cells with P-selectin via CD24 may be an important adhesion pathway in cancer metastasis.
Collapse
Affiliation(s)
- S Aigner
- Tumor Immunology Program, German Cancer Research Center, Heidelberg
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Lymphocytes from donors sensitized to soluble protein antigens tuberculin (PPD) and tetanus toxoid were stimulated in vitro with these antigens. The blasts were isolated on density gradients and maintained in long-term proliferating culture by the addition of supernatants from phytohaemagglutinin-stimulated (PHA) cultures. Blasts can be shown to retain specificity for the original stimulating antigen as measured by stimulation of DNA synthesis, but only when the antigen is presented in the company of a cooperating cell population. Autologous irradiated peripheral blood lymphocytes provide the best cooperation, but donors who share HLA-D antigens will also allow for continued proliferation in the presence of the appropriate soluble antigen. Donors sharing at HLA-A, -B, or -C show minimal ability to cooperate. The soluble antigen-specific blast cells do not manifest alloreactivity. The data are discussed with regard to possible application to clinical histocompatibility typing and to the implications of selfrecognition in the immune response.
Collapse
Affiliation(s)
- J T Kurnick
- Department of Immunology, Uppsala University, Sweden
| | | | | | | | | | | |
Collapse
|